More news from the antibiotics front. And this time, it’s overwhelmingly good. The first of a new class-type antibiotic, Zosurabalpin, is now in early trials. Today, our lead comes from the tireless Linda Geddes of The Guardian. [1] We urge you to read her excellent story, while picking just a few of the key points
From our earliest days Facebooking, then blogging in this area the great problem has been the gram negative bacteria with tough, almost leathery cell membranes which could exclude any antibiotic we could put up against them. The carbapenem class brought us few years respite. But systematic over prescription brought soaring levels of resistance. And this is what gave long faces to the scientists and doctors we used to chat with back around ’16 and ’17
As you will learn from Linda’s article, Zosorubalpin and other new antibiotics under development hope to weaken those cell walls by targeting the flow of lipopolysaccharides, thereby precluding their formation. It’s an ingenious way of re-thinking the problem, and we offer the researchers involved [2] our most heartfelt thanks. However, don’t think humanity is out of the woods. The same problems which wrecked the last generation of antibiotics could recur. Heedless over-prescription, driven by demand from ignorant, hysterical patients. Mass misuse in agriculture, in search of of short term production targets. Failure to develop successor molecule as resistance builds to Zosurabalpin and its peers. All these mistakes are out there, waiting to happen again. The scientists have given us one last chance. Have we the brains to take it?
[2]https://www.nature.com/articles/s41586-023-06799-7
#antibiotics #resistance #gram negative #zosurabalpin
Learning, Science and Society 